Notice of Intent to Publish the Reissuance of PAR-18-420, NINDS Exploratory Clinical Trials (U01 - Clinical Trial Required) (NOT-NS-21-054)

Sponsor: National Institute of Neurological Disorders and Stroke

NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed) (PAR-21-152)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is June 12, 2021.

NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required) (PAR-21-153)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is June 12, 2021.

NINDS Program Project Grant (P01 Clinical Trial Optional) (PAR-21-181)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple dates, see announcement.

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Optional) (

Sponsor: National Institute on Aging

Award: NIA intends to commit $2,250,000 in both FY 2022 and FY 2023 to fund four to six awards.

Due Date: Multiple dates, see announcement.

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease and Related Dementias (AD/ADRD) (R61/R33 Clinical Trial Require

Sponsor: National Institute on Aging

Award: NIA intends to commit $3 million in FY 2022 to fund six to eight awards.

Due Date: September 15, 2021

BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) (RFA-MH-21-1

Sponsor: National Institutes of Health

Award: Issuing IC and partner components intend to commit an estimated total of $2 million per year to fund two to four awards.

Due Date: Multiple dates, see announcement.

Advancing Research on Care and Outcome Measurement (ARCOM)

Sponsor: Alzheimer's Association

Award: $250,000

Due Date: May 5, 2021, 5 p.m. ET

3-year NIH INSPIRE Postdoctoral Fellowship at Rutgers University, on the Cognitive Neuroscience of Aging, Brain Health, and Alzheimer's Prevention

Due Date: May 1, 2021

Notice of Intent to Publish a Funding Opportunity Announcement for Joint NINDS and NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) (NOT-NS-21-050)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute of Mental Health

Notice of Intent to Publish the Reissuance of RFA-NS-18-020, BRAIN Initiative: Novel Technologies and Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) (NO

Sponsor: National Institutes of Health

Notice of Intent to Publish the Reissuance of RFA-NS-18-019, BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not A

Sponsor: National Institutes of Health

Notice of Intent to Publish the Reissuance of PAR-18-422, NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) (NOT-NS-21-055)

Sponsor: National Institute of Neurological Disorders and Stroke

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) (PAR-21-162)

Sponsor: National Institutes of Health

Due Date: August 10, 2021; February 9, 2022; August 9, 2022; February 9, 2023; August 9, 2023; February 9, 2024

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional) (RFA-MD-21-004)

Sponsor: National Institutes of Health

Award: NIMHD intends to commit $5,000,000 in FY2022 to fund six to seven awards. NCI intends to commit $1,000,000 in FY2022 to fund one award. NCCIH intends to commit $850,000 in FY2022 to fund one award. NEI intends to commit $1,000,000 in FY2022 to support one award. NHGRI intends to commit $1,700,000 in FY2022 to fund two awards. NHLBI intends to commit $1.5M to support up to two awards. NIA intends to commit $4,500,000 in FY2022 to fund six awards, including $3,000,000 to fund four awards on Alzheimer’s disease and related dementias and $1,500,000 to fund two awards on other topics. NIAAA intends to commit $850,000 in FY2022 to fund one award. NIDDK intends to commit $850,000 in FY 2022 to fund one award. NIAID intends to commit $850,000 in FY2022 to fund one award. NIAMS intends to commit $500,000 in FY2022 to fund one award. NIBIB intends to commit $800,000 in FY2022 to fund one award. NICHD intends to commit $850,000 in FY2022 to fund one award. NIDA intends to commit $2,000,000 in FY2022 to fund two awards. NIDCD intends to commit $700,000 in FY2022 to fund one award. NIDCR intends to commit $750,000 in FY2022 to fund one award. NIEHS intends to commit $850,000 in FY2022 to fund one award. NIGMS intends to commit $2,000,000 in FY2022 to fund four to six awards. NIMH intends to commit $850,000 in FY2022 to fund one award. NINDS intends to commit $850,000 in FY2022 to fund one award. NINR intends to commit $2,550,000 in FY2022 to fund three awards. The OD, OBSSR, ODP, ORWH, and SGMRO have committed funds in FY2022 towards co-funding.

Due Date: Multiple dates, see announcement.